ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2006 Financial Results on March 6, 2007
ACADIA to Host Conference Call and Webcast on Tuesday, March 6, 2007, at 5:00 p.m. Eastern Time
SAN DIEGO–(BUSINESS WIRE)–Feb. 27, 2007–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the fourth quarter and year ended December 31, 2006 on Tuesday, March 6, 2007, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Tuesday, March 6, 2007 at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and development programs.
The conference call may be accessed by dialing 866-700-7173 for participants in the U.S. or Canada and 617-213-8838 for international callers (reference passcode 55576242). A telephone replay of the conference call may be accessed through March 20, 2007 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 28337764). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there until March 20, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson’s disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA’s corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and
Chief Financial Officer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.